Source:http://linkedlifedata.com/resource/pubmed/id/10495408
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2000-5-1
|
pubmed:abstractText |
Insulin-like growth factor-I (IGF-I) has been shown to stimulate myoblast proliferation for a limited time after which serum is required to reactivate IGF-I-stimulated myoblast proliferation. The aim of these studies was to determine whether IGF-I can stimulate myoblast proliferation and/or inhibit apoptosis alone or whether co-factors are necessary. This was achieved by investigating the proliferative response of L6 myoblasts to IGF-I and horse serum (HS) and by examining the status of cells in terms of cell number, substrate adherence, cell viability and DNA laddering following incubation with IGF-I and HS. L6 myoblasts proliferate in response to IGF-I after 36 h is not due to accumulation of waste products or lack of IGF-I. The addition of a low level (1% v/v) of HS restores the ability of myoblasts to proliferate in response to IGF-I and this supports the existence of a mitogenic competence factor. Furthermore, myoblasts failing to proliferate in response to IGF-I after 36 h regain the capacity to respond to IGF-I for a further period of 36 h when exposed to fetal bovine serum. Following the initial (36 h) phase of IGF-I-stimulated proliferation, removal of both IGF-I and HS led to a dramatic (60%) reduction in the number of cells fully attached to the culture vessel, with 60% of the completely detached cells dead. Agarose gel electrophoresis of extracts from these detached cells revealed higher levels of DNA laddering than extracts prepared from attached cells with IGF-I present. This suggests that IGF-I acts as a survival factor by protecting cells from apoptosis. In conclusion these experiments support the presence of a mitogenic competence factor in horse serum, which restores the ability of cells to proliferate in response to IGF-I. Unlike proliferation, protection against apoptosis is achieved by IGF-I or HS independently of each other.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0022-0795
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
163
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
63-8
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10495408-Animals,
pubmed-meshheading:10495408-Apoptosis,
pubmed-meshheading:10495408-Cattle,
pubmed-meshheading:10495408-Cell Adhesion,
pubmed-meshheading:10495408-Cell Division,
pubmed-meshheading:10495408-Cell Line,
pubmed-meshheading:10495408-Cell Survival,
pubmed-meshheading:10495408-DNA Fragmentation,
pubmed-meshheading:10495408-Dose-Response Relationship, Drug,
pubmed-meshheading:10495408-Electrophoresis, Agar Gel,
pubmed-meshheading:10495408-Fetal Blood,
pubmed-meshheading:10495408-Humans,
pubmed-meshheading:10495408-Insulin-Like Growth Factor I,
pubmed-meshheading:10495408-Muscles,
pubmed-meshheading:10495408-Stimulation, Chemical
|
pubmed:year |
1999
|
pubmed:articleTitle |
Insulin-like growth factor-I protects myoblasts from apoptosis but requires other factors to stimulate proliferation.
|
pubmed:affiliation |
AgResearch Ltd, Private Bag 3123, Hamilton, New Zealand.
|
pubmed:publicationType |
Journal Article
|